Why Monitor Liver Function with Tigecycline
Tigecycline, a glycylcycline antibiotic for serious infections, can cause elevated liver enzymes, including cases of hepatitis and liver failure. Increased use heightens hepatotoxicity risk, especially in patients with preexisting liver issues, long-term therapy, or combination regimens. Monitoring detects early changes to prevent severe damage.
Key Liver Tests for Tigecycline Monitoring
Standard tests track hepatocellular injury and cholestasis:
- ALT (alanine aminotransferase) and AST (aspartate aminotransferase): Primary markers for liver cell damage. Tigecycline often elevates these, with levels >3x upper limit of normal signaling concern.
- ALP (alkaline phosphatase) and Total bilirubin: Assess cholestasis or mixed injury. Rising bilirubin with enzymes indicates potential failure.
- GGT (gamma-glutamyl transferase): Supports ALP elevation to confirm hepatic origin.
Perform baseline tests before starting tigecycline, then weekly during treatment, or more frequently (e.g., every 3-5 days) with increased use or risk factors like obesity or IV fluids.
Frequency and Timing Adjustments
- Short courses (7-14 days): Baseline plus end-of-therapy tests.
- Prolonged or high-dose use: Weekly ALT/AST, with bilirubin/ALP if enzymes rise.
- Discontinue if ALT >5x upper limit or bilirubin doubles with symptoms (jaundice, fatigue).
Risk Factors Prompting Closer Monitoring
Patients with chronic liver disease, alcohol use, or concurrent hepatotoxins (e.g., other antibiotics, statins) need intensified testing. Post-marketing data shows higher rates in ICU settings with tigecycline overuse for resistant infections.
What to Do if Tests Are Abnormal
Mild elevations (<3x) may resolve with dose adjustment or pause. Severe cases require stopping tigecycline and supportive care. No specific antidote exists.
[1] Tigecycline Prescribing Information, Pfizer, 2023
[2] FDA Adverse Event Reporting System (FAERS) data on tigecycline hepatotoxicity
[3] Hepatic Safety Profile of Tigecycline: A Pooled Analysis, Clinical Infectious Diseases, 2010